0
0
9/21/23 at 2:18am
Organization
Forbes
Author
Russell Flannery
29 words
0
Comments
Long R&D time-line is "unacceptable," says Memorial Sloan Kettering cancer specialist Bob Li
You are the first to view
https://www.forbes.com/sites/russellflannery/2023/09/20/fundamentally-wrong-less-than-5-of-cancer-patients-get-access-to-clinical-trials/
Create an account
or login to join the discussion